Use of Combination Measles, Mumps, Rubella, and Varicella Vaccine

Use of Combination Measles, Mumps, Rubella, and Varicella Vaccine
Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Recommendations and Reports
May 7, 2010 / 59(RR03);1-12

Prepared by

Mona Marin, MD,1 Karen R. Broder, MD,2,3 Jonathan L. Temte, MD, PhD,4 Dixie E. Snider, MD,5 Jane F. Seward, MBBS1

1Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC

2Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases (proposed), CDC

3Commissioned Corps of the U.S. Public Health Service

4University of Wisconsin, Madison, Wisconsin

5Office of Chief Science Officer, CDC



The material in this report originated in the National Center for Immunization and Respiratory Diseases, Anne Schuchat, MD, Director, and the Division of Viral Diseases, Larry Anderson, MD, Director; and the National Center for Emerging and Zoonotic Infectious Diseases (proposed), Thomas Hearn, PhD, Acting Director, and the Division of Healthcare Quality Promotion, Denise Cardo, MD, Director.

Corresponding preparer: Mona Marin, MD, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE, MS A-47, Atlanta, GA 30333. Telephone: 404-639-8791; Fax: 404-639-8665; E-mail: mmarin@cdc.gov.

Summary
This report presents new recommendations adopted in June 2009 by CDC's Advisory Committee on Immunization Practices (ACIP) regarding use of the combination measles, mumps, rubella, and varicella vaccine (MMRV, ProQuad, Merck & Co., Inc.). MMRV vaccine was licensed in the United States in September 2005 and may be used instead of measles, mumps, rubella vaccine (MMR, M-M-RII, Merck & Co., Inc.) and varicella vaccine (VARIVAX, Merck & Co., Inc.) to implement the recommended 2-dose vaccine schedule for prevention of measles, mumps, rubella, and varicella among children aged 12 months--12 years. At the time of its licensure, use of MMRV vaccine was preferred for both the first and second doses over separate injections of equivalent component vaccines (MMR vaccine and varicella vaccine), which was consistent with ACIP's 2006 general recommendations on use of combination vaccines (CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2006;55;[No. RR-15]). Since July 2007, supplies of MMRV vaccine have been temporarily unavailable as a result of manufacturing constraints unrelated to efficacy or safety. MMRV vaccine is expected to be available again in the United States in May 2010.

In February 2008, on the basis of preliminary data from two studies conducted postlicensure that suggested an increased risk for febrile seizures 5--12 days after vaccination among children aged 12--23 months who had received the first dose of MMRV vaccine compared with children the same age who had received the first dose of MMR vaccine and varicella vaccine administered as separate injections at the same visit, ACIP issued updated recommendations regarding MMRV vaccine use (CDC. Update: recommendations from the Advisory Committee on Immunization Practices [ACIP] regarding administration of combination MMRV vaccine. MMWR 2008;57:258--60). These updated recommendations expressed no preference for use of MMRV vaccine over separate injections of equivalent component vaccines for both the first and second doses.

The final results of the two postlicensure studies indicated that among children aged 12--23 months, one additional febrile seizure occurred 5--12 days after vaccination per 2,300--2,600 children who had received the first dose of MMRV vaccine compared with children who had received the first dose of MMR vaccine and varicella vaccine administered as separate injections at the same visit. Data from postlicensure studies do not suggest that children aged 4--6 years who received the second dose of MMRV vaccine had an increased risk for febrile seizures after vaccination compared with children the same age who received MMR vaccine and varicella vaccine administered as separate injections at the same visit.

In June 2009, after consideration of the postlicensure data and other evidence, ACIP adopted new recommendations regarding use of MMRV vaccine for the first and second doses and identified a personal or family (i.e., sibling or parent) history of seizure as a precaution for use of MMRV vaccine. For the first dose of measles, mumps, rubella, and varicella vaccines at age 12--47 months, either MMR vaccine and varicella vaccine or MMRV vaccine may be used. Providers who are considering administering MMRV vaccine should discuss the benefits and risks of both vaccination options with the parents or caregivers. Unless the parent or caregiver expresses a preference for MMRV vaccine, CDC recommends that MMR vaccine and varicella vaccine should be administered for the first dose in this age group. For the second dose of measles, mumps, rubella, and varicella vaccines at any age (15 months--12 years) and for the first dose at age ≥48 months, use of MMRV vaccine generally is preferred over separate injections of its equivalent component vaccines (i.e., MMR vaccine and varicella vaccine). This recommendation is consistent with ACIP's 2009 provisional general recommendations regarding use of combination vaccines (available at http://www.cdc.gov/vaccines/recs/provisional/downloads/combo-vax-Aug2009-508.pdf ), which state that use of a combination vaccine generally is preferred over its equivalent component vaccines.


open here to see the full-text (large):
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5903a1.htm?s_cid=rr5903a1_e